Literature DB >> 7780971

Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis.

M G Dole1, R Jasty, M J Cooper, C B Thompson, G Nuñez, V P Castle.   

Abstract

bcl-x is a new member of the bcl-2 gene family and is highly expressed in neural tissues. The present study was designed to determine the expression of the bcl-x gene products in neuroblastoma (NB) and their role in the modulation of chemotherapy-induced apoptosis. Twenty-seven NB cell lines were screened by quantitative immunoprecipitation for Bcl-xL, Bcl-xS, and Bcl-2 expression. None of the cell lines expressed Bcl-xS. Twenty-four of 27 (88%) of the NB cell lines expressed Bcl-xL and 21 of 27 (78%) were positive for Bcl-2. The level of Bcl-xL and Bcl-2 expression was variable among the lines analyzed. Bcl-2 expression was restricted to cells of chromaffin lineage, whereas Bcl-xL was seen in both chromaffin and nonchromaffin lines. To determine whether Bcl-xL could mediate chemotherapy resistance, a NB cell line expressing negligible levels of Bcl-xL was transfected with a bcl-xL expression vector, and unique clones were generated expressing variable levels of Bcl-xL. Cells were treated either with cisplatinum (CP), 4-hydroperoxy-cyclophosphamide (4-HC), or etoposide (VP-16) to induce apoptosis, and cell viability and DNA degradation were determined. Following treatment with CP or 4-HC, Bcl-xL-expressing cells showed significantly increased viability as compared to vector-transfected controls (P < 0.005). Flow cytometric analysis of propidium iodide-stained nuclei following CP or 4-HC treatment revealed significantly increased DNA degradation in controls as compared to Bcl-xL-expressing lines (P < 0.004). DNA analysis by pulsed-field gel electrophoresis revealed high molecular weight (approximately 40 kb) DNA degradation in controls, whereas the DNA in cells expressing Bcl-xL was largely intact. In contrast to CP and 4-HC, results with VP-16 revealed a short-term delay in the onset of apoptosis in Bcl-xL-expressing cells with no long-term survival advantage. The results of these studies indicate Bcl-xL is expressed in NB cells and functions in a manner analogous to Bcl-2 by inhibiting chemotherapy-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780971

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer.

Authors:  Shunichi Tsujitani; Hiroaki Saito; Toshiro Wakatsuki; Masahide Ikeguchi; Ken Shirabe; Masaru Morita; Yoshihiro Kakeji; Tokujiro Yano; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

Review 3.  Neuroblastoma as a neurobiological disease.

Authors:  N F Schor
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 4.  Targeting cancer cell death with a bcl-XS adenovirus.

Authors:  J S Han; G Núñez; M S Wicha; M F Clarke
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer.

Authors:  H Friess; Z Lu; A Andrén-Sandberg; P Berberat; A Zimmermann; G Adler; R Schmid; M W Büchler
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

6.  Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin.

Authors:  T Wrone-Smith; R S Mitra; C B Thompson; R Jasty; V P Castle; B J Nickoloff
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.

Authors:  T Strobel; L Swanson; S Korsmeyer; S A Cannistra
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Kaposi's sarcoma tumor cells preferentially express Bcl-xL.

Authors:  K E Foreman; T Wrone-Smith; L H Boise; C B Thompson; P J Polverini; P L Simonian; G Nunez; B J Nickoloff
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

9.  The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.

Authors:  Judith Hagenbuchner; Michael J Ausserlechner; Verena Porto; Reinhard David; Bernhard Meister; Martin Bodner; Andreas Villunger; Kathrin Geiger; Petra Obexer
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

10.  Senescence delay and repression of p16INK4a by Lsh via recruitment of histone deacetylases in human diploid fibroblasts.

Authors:  Rui Zhou; Limin Han; Guodong Li; Tanjun Tong
Journal:  Nucleic Acids Res       Date:  2009-06-26       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.